Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Sotatercept in Adults With Pulmonary Arterial Hypertension (PAH) in India
NCT07600723Phase 4Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Primary completion
- Apr 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co.. Started Oct 2026; status: recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07600723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600723.